Physicians' Academy for Cardiovascular Education
Click here to watch this as part of CME accredited course

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD, Hôpital Bichat, Paris, France - Online CME

This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

Click here to watch this as part of CME accredited course

Video navigation menu

  • FOURIER: benefit of evolocumab in patients with stable ASCVD 00:48
  • ODYSSEY OUTCOMES: results of alirocumab in patients post-ACS 03:12
  • Primary efficacy in prespecified LDL subgroups 05:30
  • ODYSSEY OUTCOMES: Safety results 06:37
  • Results in patients with ACS and diabetes 07:18

Educational information

This educational video is the second part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Other topics covered in this series

Other lectures part of this educational series are:

Faculty

Ph. Gabriel Steg is a cardiologist in the Hôpital Bichat, Paris, France. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK.

CME Accreditation

This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section

Disclosures

This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.

View slides of prof. Steg

Share this page with your colleagues and friends: